Brief: Immunicum Updates On Strategy

Mendus AB (publ)

01/10/2020 07:52

Oct 1(Reuters) - Immunicum AB  IMMUN.ST :
    * SAID ON WEDNESDAY ITS IMMUNE PRIMER CANDIDATE ILIXADENCEL
ACHIEVED CLINICAL PROOF OF CONCEPT THANKS TO MERCA STUDY
    * SAID IS IN THE RIGHT POSITION TO START OPERATING WITH A
COMMERCIAL FOCUS 
    * SAID HAS FINANCIAL RUNWAY TO DELIVER DATA-DRIVEN
VALUE-INFECTION
POINTS THROUGH TILL END OF 2021
    * IDENTIFIED GASTROINTESTINAL STROMAL TUMOURS AND SARCOMAS
AS A
DEVELOPMENT OPPORTUNITY
    * IDENTIFIED OPPORTUNITY FOR ADVANCEMENT OF ILIXADENCEL IN
KIDNEY
CANCER 
    * WILL SEEK TO EXPAND ITS PIPELINE WITH GOAL OF BECOMING A
CELL
THERAPY POWERHOUSE

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNE7pQMyT
    
 Further company coverage:  IMMUN.ST  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10))